Seoul and Gaithersburg based D&D Pharmatech is leveraging its expertise in peptide engineering for metabolic, fibrotic, and CNS conditions - including a handful of oral GLP-1 based medicines
Founder and CEO Seulki Lee describes his training in science, part of which was working on GLP-1s years ago, and the founding of the company. He walks us through D&D's pipeline, including oral GLP medicines that have been licensed to Metsera in the United States for development.